{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:01:19Z","timestamp":1780995679166,"version":"3.54.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.109985","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:06:59Z","timestamp":1778627219000},"page":"109985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of dual A2AR\/EGFR targeting pyrazoline\u2013thiazole hybrids for restored apoptotic balance in colorectal cancer"],"prefix":"10.1016","volume":"179","author":[{"given":"Noura Z.","family":"Elzoghbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa M.","family":"Kishk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf H.","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled M.","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bioorg.2026.109985_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112205","article-title":"Long non-coding RNA MIR503HG inhibits the proliferation, migration and invasion of colon cancer cells via miR-107\/Par4 axis","volume":"395","author":"Han","year":"2020","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.109985_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.genrep.2025.102163","article-title":"Molecular mechanism of angiogenesis in colorectal cancer","volume":"39","author":"Raphela-Choma","year":"2025","journal-title":"Gene Reports"},{"key":"10.1016\/j.bioorg.2026.109985_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177533","article-title":"To explore the potential combined treatment strategy for colorectal cancer: inhibition of cancer stem cells and enhancement of intestinal immune microenvironment","volume":"998","author":"Xu","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41419-020-2252-3","article-title":"B7-H3 promotes colorectal cancer angiogenesis through activating the NF-\u03baB pathway to induce VEGFA expression","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4561","key":"10.1016\/j.bioorg.2026.109985_bb0035","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/179663a0","article-title":"Fluorinated pyrimidines, a new class of tumour-inhibitory compounds","volume":"179","author":"Heidelberger","year":"1957","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109985_bb0040","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1200\/JCO.1992.10.6.896","article-title":"Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced colorectal Cancer Meta-analysis project","volume":"10","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-025-02148-4","article-title":"Invasion and metastasis in cancer: molecular insights and therapeutic targets","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109985_bb0055","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109985_bb0060","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","article-title":"Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2026.109985_bb0075","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50036","article-title":"A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity","volume":"8","author":"Palmer","year":"2019","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109985_bb0085","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s43440-023-00501-4","article-title":"Polypharmacology: promises and new drugs in 2022","volume":"75","author":"Ryszkiewicz","year":"2023","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","article-title":"Combine and conquer: challenges for targeted therapy combinations in early phase trials","volume":"14","author":"Lopez","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109985_bb0095","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S257494","article-title":"Potential impact of the multi-target drug approach in the treatment of some complex diseases","volume":"14","author":"Makhoba","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109985_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation Signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"4\u20135","key":"10.1016\/j.bioorg.2026.109985_bb0105","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","article-title":"Targeting the EGFR signaling pathway in cancer therapy: what\u2019s new in 2023?","volume":"27","author":"Halder","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"issue":"23","key":"10.1016\/j.bioorg.2026.109985_bb0110","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.32163","article-title":"Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer","volume":"125","author":"Piawah","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.109985_bb0115","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"19","key":"10.1016\/j.bioorg.2026.109985_bb0120","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/j.yexcr.2011.08.021","article-title":"EGFR-targeted therapy","volume":"317","author":"Vecchione","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bioorg.2026.109985_bb0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109985_bb0130","article-title":"Adenosine-A2A receptor pathway in Cancer immunotherapy","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.109985_bb0135","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pa.35.040195.003053","article-title":"Adenosine receptor subtypes: characterization and therapeutic regulation","volume":"35","author":"Olah","year":"1995","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2026.109985_bb0140","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coph.2020.07.005","article-title":"Oxygenation and A2AR blockade to eliminate hypoxia\/HIF-1\u03b1-adenosinergic immunosuppressive axis and improve cancer immunotherapy","volume":"53","author":"Halpin-Veszeleiova","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"issue":"5905","key":"10.1016\/j.bioorg.2026.109985_bb0150","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1164772","article-title":"The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist","volume":"322","author":"Jaakola","year":"2008","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bioorg.2026.109985_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/ph13090237","article-title":"Tumor immunotherapy using a(2A) adenosine receptor antagonists","volume":"13","author":"Zhang","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109985_bb0160","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.cell.2011.10.033","article-title":"Programmed cell death in animal development and disease","volume":"147","author":"Fuchs","year":"2011","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109985_bb0165","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.bioorg.2026.109985_bb0170","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.18632\/oncotarget.28031","article-title":"Interactions of multidomain pro-apoptotic and anti-apoptotic proteins in cancer cell death","volume":"12","author":"Chota","year":"2021","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0175","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/cdd.2017.169","article-title":"How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109985_bb0180","doi-asserted-by":"crossref","first-page":"603","DOI":"10.18632\/aging.100934","article-title":"Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies","volume":"8","author":"Pistritto","year":"2016","journal-title":"Aging (Albany NY)"},{"issue":"14","key":"10.1016\/j.bioorg.2026.109985_bb0185","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179570","article-title":"Targeting apoptotic pathways for cancer therapy","volume":"134","author":"Tian","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"19","key":"10.1016\/j.bioorg.2026.109985_bb0190","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1091\/mbc.E19-03-0136","article-title":"Adenosine interaction with adenosine receptor A2a promotes gastric cancer metastasis by enhancing PI3K-AKT-mTOR signaling","volume":"30","author":"Shi","year":"2019","journal-title":"Mol. Biol. Cell"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109985_bb0195","doi-asserted-by":"crossref","first-page":"192","DOI":"10.18632\/aging.100296","article-title":"Roles of the Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging","volume":"3","author":"Steelman","year":"2011","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0200","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","article-title":"Targeting RAS\u2013RAF\u2013MEK\u2013ERK signaling pathway in human cancer: current status in clinical trials","volume":"10","author":"Song","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.bioorg.2026.109985_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/genes10121008","article-title":"The roles of hypoxia-inducible factors and non-coding RNAs in gastrointestinal cancer","volume":"10","author":"Cho","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.bioorg.2026.109985_bb0210","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/ijms17010095","article-title":"Transactivation of epidermal growth factor receptor by G protein-coupled receptors: recent Progress, challenges and future research","volume":"17","author":"Wang","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0215","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1152\/ajpcell.00620.2005","article-title":"ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors","volume":"291","author":"Ohtsu","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109985_bb0220","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jcp.21246","article-title":"Mitogenic signaling pathways induced by G protein-coupled receptors","volume":"213","author":"Rozengurt","year":"2007","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109985_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010126","article-title":"Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation","volume":"13","author":"Sun","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"issue":"19","key":"10.1016\/j.bioorg.2026.109985_bb0235","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2174\/1568026619666190619115735","article-title":"Molecular hybridization as a tool for designing multitarget drug candidates for complex diseases","volume":"19","author":"Ivasiv","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109985_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2022.100606","article-title":"A review on biological and medicinal impact of heterocyclic compounds","volume":"4","author":"Kabir","year":"2022","journal-title":"Results Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2026.109985_bb0245","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1016\/j.bmcl.2011.07.010","article-title":"Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents","volume":"21","author":"Lv","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109985_bb0250","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejmech.2014.12.055","article-title":"A novel series of thiazolyl-pyrazoline derivatives: synthesis and evaluation of antifungal activity, cytotoxicity and genotoxicity","volume":"92","author":"Alt\u0131ntop","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109985_bb0255","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejmech.2016.02.030","article-title":"Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole\/pyrazoline-thiazolidine-based hybrids","volume":"113","author":"Havrylyuk","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109985_bb0260","doi-asserted-by":"crossref","DOI":"10.1007\/s00044-011-9685-2","article-title":"Thiazoles: having diverse biological activities","volume":"21","author":"Kashyap","year":"2012","journal-title":"Med. Chem. Res."},{"issue":"15","key":"10.1016\/j.bioorg.2026.109985_bb0265","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.4155\/fmc-2018-0416","article-title":"Thiazole in the targeted anticancer drug discovery","volume":"11","author":"Ayati","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109985_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111648","article-title":"Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors","volume":"182","author":"Sever","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109985_bb0275","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/1574892810666150708110432","article-title":"Recent patents on thiazole derivatives endowed with antitumor activity","volume":"10","author":"Morigi","year":"2015","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109985_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112016","article-title":"Thiazole-containing compounds as therapeutic targets for cancer therapy","volume":"188","author":"Sharma","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109985_bb0285","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/13543776.2012.667403","article-title":"Recent advances in the therapeutic applications of pyrazolines","volume":"22","author":"Shaaban","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109985_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22101635","article-title":"A new series of cytotoxic pyrazoline derivatives as potential anticancer agents that induce cell cycle arrest and apoptosis","volume":"22","author":"Wang","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109985_bb0295","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.21608\/erurj.2024.236943.1076","article-title":"Hybridization of thiazole and pyrazoline heterocycles, and the biological activities of their hybrid scaffolds","volume":"3","author":"Fakhry","year":"2024","journal-title":"ERU Res. J."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109985_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27030819","article-title":"Structural insight and development of EGFR tyrosine kinase inhibitors","volume":"27","author":"Amelia","year":"2022","journal-title":"Molecules"},{"issue":"5665","key":"10.1016\/j.bioorg.2026.109985_bb0305","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1126\/science.1095920","article-title":"Protein kinase inhibitors: insights into drug design from structure","volume":"303","author":"Noble","year":"2004","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109985_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189147","article-title":"Pockets as structural descriptors of EGFR kinase conformations","volume":"12","author":"Hasenahuer","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.109985_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118411","article-title":"Pharmacophore-guided review of EGFR-targeted anticancer drugs with gefitinib as a reference","volume":"303","author":"Meenu","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2026.109985_bb0320","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1111\/bph.15103","article-title":"Adenosine a(2A) receptor antagonists: from caffeine to selective non-xanthines","volume":"179","author":"Jacobson","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109985_bb0325","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00894-010-0690-z","article-title":"Pharmacophore modeling of human adenosine receptor A2A antagonists","volume":"16","author":"Xu","year":"2010","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.bioorg.2026.109985_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.crgsc.2020.100041","article-title":"Simple and solvent free practical procedure for chalcones: an expeditious, mild and greener approach","volume":"3","author":"Adnan","year":"2020","journal-title":"Curr. Res. Green Sustainable Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109985_bb0335","doi-asserted-by":"crossref","first-page":"801","DOI":"10.4103\/0250-474X.84602","article-title":"Synthesis and biological evaluation of chalcones having Heterosubstituent(s)","volume":"72","author":"Sweety","year":"2010","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109985_bb0340","first-page":"379","article-title":"A review of chalcones: synthesis, reactions, and biological importance","volume":"65","author":"Mukhtar","year":"2022","journal-title":"Egypt. J. Chem."},{"key":"10.1016\/j.bioorg.2026.109985_bb0345","first-page":"861","article-title":"Review on synthesis of bioactive pyrazoline derivatives","volume":"3","author":"Sharma","year":"2014","journal-title":"Chem. Sci. Transact."},{"key":"10.1016\/j.bioorg.2026.109985_bb0350","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejmech.2015.12.049","article-title":"Design, synthesis, and biological evaluation of novel thiazolidinediones as PPAR\u03b3\/FFAR1 dual agonists","volume":"109","author":"Darwish","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109985_bb0355","series-title":"Progress in Heterocyclic Chemistry","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/B978-0-08-100024-3.00009-X","article-title":"Chapter 5.5 - Five-Membered Ring Systems: With N and S Atom","author":"Wu","year":"2015"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109985_bb0360","first-page":"229","article-title":"Quercetin potentiates 5-fluorouracil effects in human colon cancer cells through targeting the Wnt\/\u03b2-catenin signalling pathway: the role of miR-27a","volume":"26","author":"Terana","year":"2022","journal-title":"Contemp. Oncol. (Pozn)"},{"key":"10.1016\/j.bioorg.2026.109985_bb0365","doi-asserted-by":"crossref","first-page":"28.6.1","DOI":"10.1002\/0471142727.mb2806s111","article-title":"Assaying cell cycle status using flow cytometry","volume":"111","author":"Kim","year":"2015","journal-title":"Curr. Protoc. Mol. Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109985_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196438","article-title":"An overview of technical considerations when using quantitative real-time PCR analysis of gene expression in human exercise research","volume":"13","author":"Kuang","year":"2018","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109985_bb0375","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bbamcr.2010.10.010","article-title":"Anti-apoptosis and cell survival: a review","volume":"1813","author":"Portt","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109985_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100076","article-title":"Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers","volume":"77","author":"Du","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109985_bb0385","doi-asserted-by":"crossref","first-page":"703","DOI":"10.7314\/APJCP.2016.17.2.703","article-title":"mRNA expression of Bax, Bcl-2, p53, cathepsin B, Caspase-3 and Caspase-9 in the HepG2 cell line following induction by a novel monoclonal ab Hep88 mAb: cross-talk for paraptosis and apoptosis","volume":"17","author":"Mitupatum","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.bioorg.2026.109985_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2022.101788","article-title":"Consensus combining outcomes of multiple ensemble dockings: examples using dDAT crystalized complexes","volume":"9","author":"Triches","year":"2022","journal-title":"MethodsX"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109985_bb0395","first-page":"3197","article-title":"Evaluation of IC(50) levels immediately after treatment with anticancer reagents using a real-time cell monitoring device","volume":"18","author":"Hazekawa","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109985_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245638","article-title":"Pixelwise H-score: a novel digital image analysis-based metric to quantify membrane biomarker expression from immunohistochemistry images","volume":"16","author":"Ram","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.109985_bb0405","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13000-014-0221-9","article-title":"Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review","volume":"9","author":"Fedchenko","year":"2014","journal-title":"Diagn. Pathol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:16:18Z","timestamp":1780992978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826005213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":81,"alternative-id":["S0045206826005213"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109985","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of dual A2AR\/EGFR targeting pyrazoline\u2013thiazole hybrids for restored apoptotic balance in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109985"}}